Content about Pharmaceutical industry in India

February 19, 2014

The Food and Drug Administration announced the initiation of the Secure Supply Chain Pilot Program to enhance the security of imported drugs.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced the initiation of the Secure Supply Chain Pilot Program to enhance the security of imported drugs. 

In August 2013, the FDA published a notice in the Federal Register (78 FR 51192) to solicit companies to voluntarily submit applications for participation in this two-year program. Thirteen prequalified companies have now been designated to take part, and will receive expedited entry for the importation of up to five selected drug products into the United States.

December 17, 2013

Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

BURLINGTON, Mass. — Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

August 26, 2013

Biotech company Amgen is buying Onyx Pharmaceuticals, the companies said Sunday.

THOUSAND OAKS, Calif. — Biotech company Amgen is buying Onyx Pharmaceuticals, the companies said Sunday.

Onyx, based in South San Francisco, Calif., has a portfolio of cancer drugs, including the injected multiple myeloma drug Kyprolis (carfilzomib), as well as Nexavar (sorafenib) tablets, developed with Bayer HealthCare Pharmaceuticals; Stivarga (regorafenib) tablets, developed by Bayer; and palbociclib, developed by Pfizer.

June 20, 2013

Tris Pharma has hired a former buyer from AmerisourceBergen to head its generic drug business, the company said.

MONMOUTH JUNCTION, N.J. — Tris Pharma has hired a former buyer from AmerisourceBergen to head its generic drug business, the company said.

Tris announced the appointment of Janet Penner as president of the new generic pharmaceuticals business, which will have its own sales, marketing and distribution and will be responsible for bringing drugs to market. So far, the Food and Drug Administration has approved 13 of Tris' generics, including several first-to-market products.

June 4, 2013

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

ARLINGTON, Va. — The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

February 5, 2013

Cardinal Health posted $25.2 billion in revenue for its 2013 second quarter, down 7%. The company's non-GAAP diluted earnings per share was up 15% to $0.93.

DUBLIN, Ohio — Cardinal Health on Tuesday posted $25.2 billion in revenue for its 2013 second quarter, down 7%. The company's non-GAAP diluted earnings per share was up 15% to $0.93. 

November 26, 2012

Ranbaxy Labs has launched a new treatment for acne under a licensing agreement with a Canadian drug maker.

PRINCETON, N.J. — Ranbaxy Labs has launched a new treatment for acne under a licensing agreement with a Canadian drug maker.

Ranbaxy announced Monday the launch of Absorbica (isotretinoin) capsules for treating severe recalcitrant nodular acne in patients ages 12 years and older. The drug was launched under a license from Mississauga, Ontario-based Cipher Pharmaceuticals.

Normally, oral isotretinoin must be taken with a high-fat meal due to its chemical properties, but Absorbica is designed to be taken without food.